Edition:
India

Cytori Therapeutics Inc (CYTX.OQ)

CYTX.OQ on NASDAQ Stock Exchange Capital Market

0.35USD
17 Jan 2018
Change (% chg)

-- (--)
Prev Close
$0.35
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
254,704
52-wk High
$2.13
52-wk Low
$0.22

Select another date:

Thu, Jan 11 2018

BRIEF-Swissquote Bank Sells 188,426 Shares Of Cytori Therapeutics Inc's Common Stock Between Jan 9-11

* SWISSQUOTE BANK SA REPORTS OPEN MARKET SALE OF 188,426 SHARES OF CYTORI THERAPEUTICS INC'S COMMON STOCK BETWEEN JAN 9 AND JAN 11 - SEC FILING Source text: (http://bit.ly/2ExdrAg) Further company coverage:

BRIEF-Swissquote Bank SA Reports 12 pct Passive Stake In Cytori Therapeutics As Of Dec. 29, 2017

* SWISSQUOTE BANK SA REPORTS 12 PERCENT PASSIVE STAKE IN CYTORI THERAPEUTICS INC AS OF DECEMBER 29, 2017 - SEC FILING‍​ Source text - (http://bit.ly/2CUutMr) Further company coverage:

BRIEF-Cytori Therapeutics Inc ‍announces new investigator initiated U.S. clinical trial for hip osteonecrosis​

* Cytori Therapeutics Inc - ‍announced a new investigator initiated U.S. clinical trial for hip osteonecrosis​ Source text for Eikon: Further company coverage:

BRIEF-Cytori reports Q3 loss per share $0.14

* Cytori reports third quarter 2017 business and financial results

BRIEF-Cytori Therapeutics enters into an amendment to its existing loan and security agreement

* Cytori Therapeutics- On September 20, 2017, co entered into an amendment to its existing loan and security agreement, dated May 29, 2015 - SEC filing

BRIEF-Cytori announces corporate restructuring & cost reduction plan

* Cytori announces corporate restructuring & cost reduction plan

BRIEF-Cytori Therapeutics Q2 loss per share $0.19

* Cytori reports second quarter 2017 business and financial results

BRIEF-Cytori announces top-line 24- and 48-week results

* Cytori announces top-line 24- and 48-week results from the star trial of habeo cell therapy in patients with scleroderma

Select another date: